JP2024507948A5 - - Google Patents

Info

Publication number
JP2024507948A5
JP2024507948A5 JP2023552013A JP2023552013A JP2024507948A5 JP 2024507948 A5 JP2024507948 A5 JP 2024507948A5 JP 2023552013 A JP2023552013 A JP 2023552013A JP 2023552013 A JP2023552013 A JP 2023552013A JP 2024507948 A5 JP2024507948 A5 JP 2024507948A5
Authority
JP
Japan
Prior art keywords
sequence
seq
sequence shown
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023552013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507948A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/017945 external-priority patent/WO2022183018A1/en
Publication of JP2024507948A publication Critical patent/JP2024507948A/ja
Publication of JP2024507948A5 publication Critical patent/JP2024507948A5/ja
Pending legal-status Critical Current

Links

JP2023552013A 2021-02-26 2022-02-25 呼吸器ウイルス感染症に対する防御抗体 Pending JP2024507948A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163154166P 2021-02-26 2021-02-26
US63/154,166 2021-02-26
PCT/US2022/017945 WO2022183018A1 (en) 2021-02-26 2022-02-25 Protective antibodies against respiratory viral infections

Publications (2)

Publication Number Publication Date
JP2024507948A JP2024507948A (ja) 2024-02-21
JP2024507948A5 true JP2024507948A5 (enExample) 2025-03-05

Family

ID=83048466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023552013A Pending JP2024507948A (ja) 2021-02-26 2022-02-25 呼吸器ウイルス感染症に対する防御抗体

Country Status (7)

Country Link
US (1) US20240150444A1 (enExample)
EP (1) EP4297780A4 (enExample)
JP (1) JP2024507948A (enExample)
KR (1) KR20230148418A (enExample)
AU (1) AU2022227761A1 (enExample)
CA (1) CA3209869A1 (enExample)
WO (1) WO2022183018A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US20250304657A1 (en) * 2022-08-29 2025-10-02 Fred Hutchison Cancer Center Antibodies with novel fc modification combinations that increase antibody function
WO2024077268A2 (en) * 2022-10-07 2024-04-11 Fred Hutchinson Cancer Center Human metapneumovirus antibodies and uses thereof
WO2025165833A1 (en) * 2024-01-29 2025-08-07 Vanderbilt University Hpiv3-neutralizing antibodies and methods of use thereof
CN119039429B (zh) * 2024-08-27 2025-10-03 浙江大学 一种抗RBD单链抗体No.35及制备抗体偶联药物的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3279215B1 (en) * 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
KR102149069B1 (ko) * 2012-03-20 2020-08-28 후맙스 바이오메드 에스에이 Rsv, mpv 및 pvm를 중화하는 항체 및 이의 용도
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US11312761B2 (en) * 2016-10-21 2022-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2019165019A1 (en) * 2018-02-21 2019-08-29 Vanderbilt University Antibodies to human respiratory syncytial virus protein f pre-fusion conformation and methods of use therefor
PH12021553101A1 (en) * 2019-06-12 2023-10-02 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
US20250304657A1 (en) * 2022-08-29 2025-10-02 Fred Hutchison Cancer Center Antibodies with novel fc modification combinations that increase antibody function

Similar Documents

Publication Publication Date Title
JP2012504955A5 (enExample)
JP2010516229A5 (enExample)
JP2023515271A5 (enExample)
AU2016307967B2 (en) Tissue factor pathway inhibitor antibodies and uses thereof
RU2009129403A (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
JP2011528902A5 (enExample)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2018535650A5 (enExample)
JP2023523549A (ja) SARS-CoV-2に対する抗体およびそれを使用する方法
JP2010534478A5 (enExample)
JP2020524661A5 (enExample)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
JP2014519334A5 (enExample)
JP2021533159A5 (enExample)
JP2021534797A5 (enExample)
US20250263467A1 (en) Antibody therapies for sars-cov-2 infection
JP2021531732A5 (enExample)
JP2013521252A5 (enExample)
JP2023542107A (ja) SARS-CoV-2を標的とするシングルドメイン抗体
JP2024507948A (ja) 呼吸器ウイルス感染症に対する防御抗体
JP2025514978A5 (enExample)
CN116194083A (zh) 抗冠状病毒抗体和其用途
JP2015511216A5 (enExample)
IL322846A (en) Antibodies, antigen-binding fragments and methods of use
JP2024518536A5 (enExample)